Listing 13.24 Prostate Cancer in 2026

Q: Does newly diagnosed prostate cancer qualify for SSDI?

Usually no. Localized prostate cancer has 99%+ 5-year survival and does not meet the listing. Metastatic disease may qualify when it progresses despite hormone therapy (mCRPC), has visceral metastases, or is small-cell histology.

Q: What does castration-resistant mean?

Disease that progresses despite testosterone suppression below 50 ng/dL. Progression can be biochemical (rising PSA), radiographic (new lesions), or clinical (worsening symptoms).

Q: Are bone metastases considered visceral for 13.24B?

No. Bone and lymph node metastases alone do not meet Paragraph B. Visceral means liver, lung, brain, adrenal, or other solid organ. Bone-only disease has to meet Paragraph A instead.

Q: Does hormone therapy alone qualify me for SSDI?

No. Being on ADT does not meet the listing. The listing requires progression despite ADT, or visceral metastases, or small-cell histology.

Q: How is PSA progression defined?

PCWG3 criteria: three consecutive PSA rises at least 1 week apart, second and third rises 50% over nadir, absolute PSA at least 2 ng/mL. Measured with testosterone confirmed castrate.

Q: What treatments come after failing hormone therapy?

Second-generation anti-androgens (abiraterone, enzalutamide, apalutamide, darolutamide), taxane chemotherapy, lutetium-177 PSMA radioligand, PARP inhibitors for HRR-mutated disease, immunotherapy for MSI-high.

Q: What are the long-term effects of ADT?

Bone density loss (30-50% osteoporosis at 5 years), sarcopenia, metabolic syndrome (40-60%), cardiovascular risk, cognitive impairment (20-30%), fatigue (50-60%), hot flashes, depression (25-30%).

By Anthony Albert, Benefits Research Director at Disability Exchange. Published 2026-07-27. About 3,000 words.

Prostate cancer is the most common non-skin cancer in American men. The American Cancer Society projects 313,780 new prostate cancer diagnoses and 35,770 deaths in 2026, making it the second leading cause of cancer death in men behind lung cancer. Overall 5-year relative survival is 97% (99%+ for local and regional, dropping sharply to 34% for distant metastatic disease).

SSA Listing 13.24 recognizes three separate ways prostate cancer meets the medical vocational disability rules. The paragraphs are narrower than most cancer listings because early prostate cancer often has an indolent course that does not meet SSDI criteria. This is a full walkthrough of each paragraph, the evidence you need, the durational rules, and how modern treatments shape residuals at CDR.

Diagnosed with advanced prostate cancer? See if you qualify for SSDI in 60 seconds.
See If You Qualify

The three paragraphs of Listing 13.24

Paragraph A: Progressive or recurrent despite hormonal intervention

Paragraph A covers what oncologists call metastatic castration-resistant prostate cancer (mCRPC) or non-metastatic castration-resistant prostate cancer (nmCRPC). The listing text is:

"Prostate gland cancer that is progressive or recurrent despite initial hormonal intervention."

Two elements are required:

Element 1: Initial hormonal intervention. This means androgen deprivation therapy (ADT) via one of:

Surgical castration (bilateral orchiectomy)
LHRH agonists (leuprolide, goserelin, triptorelin, histrelin)
LHRH antagonists (degarelix, relugolix oral)
Combined androgen blockade (ADT + bicalutamide, flutamide, or nilutamide)

Adequate hormonal intervention means testosterone suppressed to castrate levels (<50 ng/dL, ideally <20 ng/dL under current AUA guidelines).

Element 2: Progression despite that intervention. Progression can be defined three ways:

Biochemical progression: PSA rising over the nadir on castrate testosterone. Prostate Cancer Working Group (PCWG3) criteria require three consecutive PSA rises at least 1 week apart, with the second and third rises 50% over the nadir, and absolute PSA at least 2 ng/mL.
Radiographic progression: new lesions on bone scan (2+ new lesions confirmed on second scan) or soft tissue progression per RECIST 1.1 (20% growth in target lesions).
Clinical progression: worsening pain requiring dose escalation, new pathologic fracture, spinal cord compression, or ureteric obstruction from local progression.

Any one of the three types of progression on castrate testosterone meets 13.24A. This is the most common route to SSDI approval for prostate cancer.

Paragraph B: Visceral metastases

Paragraph B qualifies when there are metastases to visceral organs. Visceral means:

Liver
Lung
Brain
Adrenal (rare)
Any solid organ other than bone or nodes

Bone metastases and lymph node metastases alone do NOT meet 13.24B. This is important because prostate cancer's most common metastatic pattern is bone (80-90% of metastatic cases involve bone). Bone-only disease would need to progress despite hormone therapy to meet 13.24A rather than 13.24B.

Visceral metastases in prostate cancer typically indicate more aggressive disease biology (often neuroendocrine differentiation or DNA repair pathway mutations like BRCA2, ATM, or CDK12). Prognosis with visceral involvement is worse than bone-only, with median overall survival dropping from 30+ months to 12-18 months.

Evidence requirements: CT chest/abdomen/pelvis or PET-CT (either PSMA-PET or FDG-PET, PSMA preferred for prostate cancer) showing visceral lesions with pathologic confirmation via biopsy when clinically feasible, or high clinical suspicion with PSA rise and imaging pattern typical of metastatic disease.

Paragraph C: Small-cell (oat cell) carcinoma

Paragraph C covers small-cell carcinoma of the prostate, an extremely rare and aggressive neuroendocrine variant. Two clinical settings:

De novo small-cell prostate carcinoma: less than 1% of prostate cancers at initial diagnosis. Pathology shows small-cell histology with neuroendocrine markers (chromogranin A, synaptophysin, CD56, INSM1).
Treatment-emergent neuroendocrine prostate cancer (t-NEPC): transformation from adenocarcinoma under sustained ADT pressure, typically after years of hormone therapy. 10-20% of mCRPC develops some neuroendocrine features on repeat biopsy. Pure small-cell transformation is less common but qualifies under 13.24C when confirmed.

Any confirmed small-cell (oat cell) prostate carcinoma meets 13.24C regardless of stage or hormone status.

Diagnostic evidence required

SSA requires objective medical evidence for every 13.24 approval:

Pathology report confirming prostate carcinoma with Gleason grade (Gleason score 6-10, or Grade Group 1-5 under 2014 ISUP system): Grade Group 1 (Gleason 6), Group 2 (3+4=7), Group 3 (4+3=7), Group 4 (Gleason 8), Group 5 (Gleason 9-10)
PSA history: baseline at diagnosis, nadir on treatment, and current values with dates. PSA doubling time (PSADT) calculation for nmCRPC classification (PSADT ≤10 months = high risk).
Staging imaging: bone scan (Tc-99m MDP), CT chest/abdomen/pelvis, MRI pelvis (multiparametric), PSMA-PET (68Ga-PSMA-11 or 18F-DCFPyL/piflufolastat) increasingly standard for staging high-risk disease and restaging biochemical recurrence
Testosterone level at time of PSA progression (must be castrate <50 ng/dL for CRPC classification)
Treatment history: ADT method (surgical vs medical), duration, response, addition of second-generation anti-androgens (abiraterone, enzalutamide, apalutamide, darolutamide), chemotherapy (docetaxel, cabazitaxel), radioligand (lutetium-177 PSMA), PARP inhibitors for HRR-mutated disease (olaparib, rucaparib, talazoparib), immunotherapy (sipuleucel-T, pembrolizumab for MSI-high)
Genetic testing: germline BRCA1/BRCA2/ATM/CHEK2/PALB2 for hereditary risk; somatic tumor testing (HRR panel, MSI, TMB) for targeted therapy eligibility

The Compassionate Allowance overlay

Two prostate cancer categories are on the current 2026 CAL list:

Metastatic castration-resistant prostate cancer (mCRPC)
Small-cell carcinoma of the prostate

CAL cases get expedited processing (target 14-30 days for initial decision). This means patients who meet 13.24A with metastatic disease and have failed initial hormone therapy get flagged automatically for fast-track review.

Metastatic hormone-sensitive prostate cancer (mHSPC) is NOT on the CAL list. It has to progress to castration-resistant status before CAL kicks in. But many DDS offices process mHSPC cases quickly anyway given the metastatic burden and expected prognosis.

Modern treatment residuals for the CDR

The three-year remission rule under 13.00H1 applies. After 3 years without evidence of active disease, SSA presumes medical improvement and shifts to residual analysis. In prostate cancer specifically, true 3-year remission is uncommon at the mCRPC stage - most patients have chronic ongoing disease control rather than remission. Residuals from prolonged treatment become the driver of ongoing disability.

Long-term androgen deprivation effects

Sustained ADT (surgical castration or LHRH therapy for 3+ years) produces a well-documented syndrome:

Bone density loss: 4-5% annual reduction in first year, cumulative osteoporosis in 30-50% at 5 years. Fracture risk 20-40% higher than age-matched controls. Can qualify under 1.19 pathologic fracture listing if fractures accumulate.
Sarcopenia (muscle loss): 2-4% annual, contributing to functional decline and fall risk
Metabolic syndrome: 40-60% develop weight gain, insulin resistance, dyslipidemia. Diabetes incidence increases 40% over 5 years of ADT.
Cardiovascular: increased risk of MI, stroke, and cardiovascular death, particularly in patients with preexisting cardiac disease. Can support qualification under 4.02 or 4.04 at CDR.
Cognitive impairment: mild to moderate cognitive changes in 20-30% of long-term ADT patients, particularly executive function and processing speed. Documented under 12.02 neurocognitive listings at CDR when severe.
Fatigue: chronic fatigue in 50-60% of long-term ADT patients, significant functional impact
Hot flashes: 70-80% incidence, disruptive for sleep and daily function
Erectile dysfunction and loss of libido: near universal
Depression: 25-30% incidence, higher than age-matched controls. Documented under 12.04 at CDR.

Second-generation anti-androgens

Abiraterone, enzalutamide, apalutamide, darolutamide add to ADT toxicity:

Abiraterone: hypertension (30-40%), hypokalemia (15-20%), fluid retention (15-20%), hepatotoxicity (5-10%), adrenal insufficiency (requires prednisone or dexamethasone concurrent dosing)
Enzalutamide: fatigue (35-50%), seizure (0.5-1%), falls (10-15%), hypertension (10-15%), cognitive impairment (10-20%)
Apalutamide: rash (25%), thyroid dysfunction (10-15%), fracture (10%), falls (15-20%)
Darolutamide: better tolerated overall but still adds fatigue and fracture risk

Chemotherapy

Docetaxel and cabazitaxel produce peripheral neuropathy (30-50%), neutropenia, fatigue, and long-term cognitive impact. Grade 3 CIPN can qualify under 11.14 at CDR.

Lutetium-177 PSMA radioligand therapy

Pluvicto (lutetium-177 vipivotide tetraxetan) approved March 2022 for PSMA-positive mCRPC after taxane and anti-androgen failure. Toxicities: xerostomia (dry mouth 40-60%, sometimes permanent), fatigue (40%), nausea, cytopenias (thrombocytopenia and anemia 15-25%), renal impairment (5-10% cumulative). Severe xerostomia interfering with speech and swallowing can support ongoing disability past 3-year mark.

PARP inhibitors (olaparib, rucaparib, talazoparib)

Used for HRR-mutated mCRPC (BRCA1/2, ATM, PALB2 most common). Toxicities: anemia (30-40% grade 3+), fatigue (50-70%), nausea (50-70%), thrombocytopenia (10-20% grade 3+), risk of MDS/AML (1-2% at 2+ years exposure). Chronic anemia requiring transfusion can qualify under 7.05 chronic anemia at CDR.

Radiation cystitis and proctitis

Post-radiation urinary and rectal complications occur in 10-20% of patients who had definitive external beam radiation or brachytherapy. Chronic radiation cystitis with hematuria, incontinence, or urinary frequency can qualify under 6.06 nephrotic syndrome or the genitourinary residual analysis. Chronic radiation proctitis with bleeding, urgency, or fecal incontinence can qualify under 5.06 IBD or 5.08 short bowel analogy.

Worked case examples

Case 1: Robert, 68, Florida, mCRPC on second-line abiraterone

Robert was diagnosed with Gleason 4+5=9 prostate cancer in 2022 with bone metastases at initial presentation (pelvis, spine, ribs). Started ADT (leuprolide) plus docetaxel per CHAARTED regimen. PSA nadir 0.8 ng/mL at 9 months. PSA rise to 4.2 by month 24 despite castrate testosterone (18 ng/dL). Now meets biochemical progression definition on castrate T. Bone scan showed 2 new pelvic lesions at month 26. Started abiraterone + prednisone.

SSDI application filed month 27. Listing 13.24A met (progressive despite initial hormonal intervention). Also flagged as CAL (metastatic castration-resistant prostate cancer). Approval 18 days at Florida DDS. Onset backdated to first PSA rise on castrate T.

Case 2: William, 74, Ohio, small-cell transformation after 5 years of ADT

William had Gleason 4+4=8 adenocarcinoma diagnosed 2020, treated with prostatectomy + radiation + ADT. Achieved PSA nadir 0.02. In 2025 developed pelvic pain and new liver lesions on CT despite continued castrate T. Liver biopsy showed small-cell neuroendocrine carcinoma with chromogranin+ synaptophysin+ INSM1+. PSA still low (0.5 ng/mL) which is typical of small-cell transformation (neuroendocrine tumors do not make PSA).

Listing 13.24B (visceral - liver metastases) AND 13.24C (small-cell transformation) both met. CAL for small-cell prostate. SSDI filed 2026. Approved 12 days at Ohio DDS. Started platinum + etoposide chemotherapy for small-cell histology.

Case 3: James, 58, Michigan, BRCA2+ mCRPC on olaparib

James was diagnosed with Gleason 4+5=9 prostate cancer in 2023 with high-volume bone metastases plus supraclavicular nodes. Germline testing revealed BRCA2 pathogenic variant. Somatic testing confirmed BRCA2 in tumor. Started ADT + abiraterone (per PROpel and MAGNITUDE trials). PSA nadir 0.1. Progression at 18 months with new bone lesions and PSA rise on castrate T. Started olaparib per PROfound trial.

Listing 13.24A met at progression on castrate T. CAL fast-track applied. Approved 20 days at Michigan DDS. Ongoing olaparib with grade 2 anemia (Hgb 8-9) requiring occasional transfusion.

What to file with your application

Prostate biopsy pathology with Gleason grade / Grade Group
Radical prostatectomy pathology if applicable
PSA history table showing baseline, nadir, and progression values with dates
Testosterone levels showing castrate suppression
Bone scan and CT/MRI reports showing metastatic disease
PSMA-PET report if available
Oncology consultation notes with treatment plan and response assessment
Genetic testing results (germline and/or somatic) if performed
Any hospital admission records for treatment complications
Current medication list

Filing for SSDI with advanced prostate cancer?
Free eligibility review in 60 seconds.
See If You Qualify

Frequently asked questions

Does newly diagnosed prostate cancer qualify for SSDI?

Usually no. Localized prostate cancer treated with surgery or radiation has excellent 5-year survival (99%+) and does not typically meet the listing. Metastatic prostate cancer at initial diagnosis (mHSPC) may qualify if it progresses despite hormone therapy (converting to mCRPC), if there are visceral metastases at diagnosis, or if the histology is small-cell.

What does castration-resistant mean?

Castration-resistant prostate cancer (CRPC) is disease that progresses despite testosterone suppression to castrate levels (<50 ng/dL, ideally <20 ng/dL). Progression can be biochemical (rising PSA), radiographic (new lesions), or clinical (worsening symptoms). Any of the three types on castrate testosterone meets the CRPC definition.

Are bone metastases considered visceral for 13.24B?

No. Bone metastases and lymph node metastases alone do not meet Paragraph B. Visceral means liver, lung, brain, adrenal, or other solid organ. Bone-only metastatic disease has to meet Paragraph A (progressive despite hormone therapy) instead.

Does hormone therapy alone qualify me for SSDI?

Not by itself. Being on ADT (LHRH agonist, orchiectomy, or antagonist) does not meet the listing. The listing requires progression despite ADT, or visceral metastases, or small-cell histology.

How is PSA progression defined?

Prostate Cancer Working Group (PCWG3) criteria require three consecutive PSA rises at least 1 week apart, with the second and third rises 50% over the nadir, and absolute PSA at least 2 ng/mL. This is measured with testosterone confirmed castrate.

What treatments come after failing hormone therapy?

Second-generation anti-androgens (abiraterone, enzalutamide, apalutamide, darolutamide), taxane chemotherapy (docetaxel, cabazitaxel), lutetium-177 PSMA radioligand (Pluvicto for PSMA-positive after taxane), PARP inhibitors (olaparib, rucaparib, talazoparib for HRR-mutated), immunotherapy (sipuleucel-T, pembrolizumab for MSI-high). Sequencing depends on genetics and prior therapy.

What are the long-term effects of ADT?

Bone density loss (30-50% osteoporosis at 5 years), sarcopenia, metabolic syndrome (40-60%), cardiovascular risk increase, cognitive impairment (20-30% mild to moderate), fatigue (50-60%), hot flashes (70-80%), depression (25-30%), erectile dysfunction and loss of libido (near universal). Many of these support ongoing disability past initial approval.

Next steps

If you are dealing with advanced prostate cancer, file for SSDI as soon as you have documentation of progression on hormone therapy, visceral metastases, or small-cell histology. Do not wait for further progression. The earlier you file, the sooner your entitlement clock starts and back pay accumulates.

Ready to file?
Free eligibility check in 60 seconds.
See If You Qualify

Disclosure: This is a privately owned website and is not affiliated with or endorsed by the Social Security Administration (SSA). Disability Exchange is an independent information resource. Information here is educational and not legal advice.